Episodic Migraine
Conditions
Brief summary
Change from baseline in MMD to week 9 through week 12 (month 3) of the DBTP.
Detailed description
Change from baseline in monthly headache days to week 9 through week 12 (month 3) of the DBTP., Achievement of at least 50% reduction in MMD from baseline to week 9 through week 12 (month 3) of the DBTP, Change from baseline in MMD to the average of the first 3 months (week 1 through week 12) of the DBTP., Change from baseline in monthly average severity of migraine attacks to week 9 through week 12 (month 3) of the DBTP., Change from baseline in migraine related disability and productivity as measured by the modified PedMIDAS to week 9 through week 12 (month 3) of the DBTP.
Interventions
DRUGErenumab
Sponsors
Amgen Inc.
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in MMD to week 9 through week 12 (month 3) of the DBTP. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in monthly headache days to week 9 through week 12 (month 3) of the DBTP., Achievement of at least 50% reduction in MMD from baseline to week 9 through week 12 (month 3) of the DBTP, Change from baseline in MMD to the average of the first 3 months (week 1 through week 12) of the DBTP., Change from baseline in monthly average severity of migraine attacks to week 9 through week 12 (month 3) of the DBTP., Change from baseline in migraine related disability and productivity as measured by the modified PedMIDAS to week 9 through week 12 (month 3) of the DBTP. | — |
Countries
Belgium, Germany, Hungary, Italy, Poland, Portugal, Spain
Outcome results
None listed